BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
27 hedge funds and large institutions have $3.94M invested in BRAINSTORM CELL THERAPUTC in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
125% more call options, than puts
Call options by funds: $18K | Put options by funds: $8K
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
25% more capital invested
Capital invested by funds: $3.14M → $3.94M (+$800K)
13% more funds holding
Funds holding: 24 → 27 (+3)
0.55% more ownership
Funds ownership: 0% → 0.55% (+0.55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$924K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$91.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24K |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
+$14.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$448K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$51K |
| 3 |
GCAC
Guardian Capital Advisors (Canada)
Toronto,
Ontario, Canada
|
-$24K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$20.8K |
| 5 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $1K | – | – | – |
|
27
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$51K | -1,427 | Closed |
|
|
GCAC
29
Guardian Capital Advisors (Canada)
Toronto,
Ontario, Canada
| – | -$24K | -667 | Closed |
|
|
TWA
30
TCI Wealth Advisors
Tucson,
Arizona
| – | -$3K | -73 | Closed |
|
BCLI Hedge Fund Activity: Q4 2016 in Review
27 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2016, worth a combined $3.94M — up 25% from $3.14M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BCLI positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $924K. The largest seller was Sabby Management, cutting an estimated $448K.
- 27 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2016, up from 24 in Q3 2016.
- Funds reported $3.94M of BRAINSTORM CELL THERAPUTC stock for Q4 2016, up 25% quarter-over-quarter.
- 6 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2016 and 3 closed out, a net change of +3 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2016 was Perceptive Advisors, an estimated $924K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2016 was Sabby Management, an estimated $448K sold.
Based on aggregated 13F filings for Q4 2016.